Wednesday, 15 Aug 2018

You are here

Ultrasound Tenosynovitis Predicts RA Development

Musculoskeletal ultrasound (US) has become a more widely used tool in rheumatology clinical practice.  This study of early inflammatory arthritis patients shows that US-defined digit flexor tenosynovitis (TS) was more predictive of subsequent rheumatoid arthritis (RA) than findings of ACPA positivity or US-defined joint synovitis.

A cohort of 107 early arthritis patients underwent baseline clinical, laboratory and US assessment of 19 bilateral joint sites and 16 bilateral tendon compartments. Ultimate outcomes were determined 18 months later using the 2010 ACR/EULAR classification criteria for RA.

A total of 46/107 patients developed persistent RA, 17 patients developed non-RA persistent disease and 44 patients had resolved their disease at follow-up.

US-defined TS was more likely in RA, but was seen in all groups studied (RA 85%, non-RA persistent disease 71% and resolving 70%). RA patients were more likely to have grey scalle (GS) and power doppler (PD) changes at PIP 1–5, MCP 1–5, wrist, elbow, MTP 3 and MTP 5 joints. In addition, RA patients were more likely to have MTP 2 PD changes, but not GS changes alone, compared with patients with resolving arthritis.

On multi-variate analysis, US-defined digit flexor TS provided independent predictive data over and above the presence of ACPA and US-defined joint synovitis.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Tumor Necrosis Factor Inhibitors Do Not Increase the Risk of Cancer Recurrence

There is a large body of data that shows tumor necrosis factor inhibitors (TNFi) use in rheumatoid arthritis (RA) confers the same risk as that seen in RA - meaning there is no increase over and above that incurred by inflammation and RA itself.  There are fewer studies about whether it is safe to use a TNFi in someone with a pre-existing history of cancer.

Cardiovascular Benefits of Maintaining Biologic Therapy

An Australian prospective study of patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) has shown that sustained use of tumour necrosis factor (TNFi) inhibitors or biologics can reduce the risks of cardiovascular events (CVEs).

Maternal RA Increases Offspring Risk of Autoimmune Disorders

A Danish population study suggests that fetal exposure to maternal rheumatoid arthritis results in an increased offspring risk of thyroid disease, epilepsy and RA, compared to children born to mothers without RA.

The Fate of Palindromic Rheumatism

 

Palindromic rheumatism (PR) is an intermittent inflammatory arthropathy with episodes of arthritis and/or periarticular inflammation that wax and wane over time. It is thought that up to one-third of such patients may go on to develop rheumatoid arthritis (RA).

Consensus Guidelines for Methotrexate in Juvenile Idiopathic Arthritis

A consensus panel was convened to develop consensus-based clinical and therapeutic recommendations for the use of methotrexate (MTX) in the management of Juvenile Idiopathic Arthritis (JIA) patients.